What the FDA labels say about taking them together
Cobicistat, darunavir, emtricitabine and tenofovir alafenamide and pitavastatin
Cobicistat, darunavir, emtricitabine and tenofovir alafenamide's FDA label of April 17, 2026 names pitavastatin in its drug interactions section; the pitavastatin labels PlainMeds reads (2) do not name cobicistat, darunavir, emtricitabine and tenofovir alafenamide. The cobicistat, darunavir, emtricitabine and tenofovir alafenamide label: “For atorvastatin, fluvastatin, pitavastatin, pravastatin, and rosuvastatin, start with the lowest recommended dose and titrate while monitoring for safety.”
Check it at the source: the cobicistat, darunavir, emtricitabine and tenofovir alafenamide FDA label on DailyMed (effective April 17, 2026, Janssen Products LP); the pitavastatin FDA label on DailyMed (effective March 31, 2026, Kowa Pharmaceuticals America, Inc.).
What does the cobicistat, darunavir, emtricitabine and tenofovir alafenamide label say about pitavastatin?
Cobicistat, darunavir, emtricitabine and tenofovir alafenamide label, drug interactionsConcomitant Drug Class/Drug Name Examples: e.g., atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin; Effect on Concentration: ↑ atorvastatin ↑ fluvastatin ↑ pravastatin ↑ rosuvastatin pitavastatin: effect unknown; Clinical Comment: For atorvastatin, fluvastatin, pitavastatin, pravastatin, and rosuvastatin, start with the lowest recommended dose and titrate while monitoring for safety.
Source: FDA drug label (Symtuza), Janssen Products LP, effective April 17, 2026 (SPL set 85a17d00-6b7c-41ea-a6b3-5ad924820dab), via openFDA; the full label on DailyMed
What does the pitavastatin label say about cobicistat, darunavir, emtricitabine and tenofovir alafenamide?
Pitavastatin's label (effective March 31, 2026) and its 1 other brand-application label do not name cobicistat, darunavir, emtricitabine and tenofovir alafenamide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Livalo), Kowa Pharmaceuticals America, Inc., effective March 31, 2026 (SPL set 44dcbf97-99ec-427c-ba50-207e0069d6d2), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cobicistat, darunavir, emtricitabine and tenofovir alafenamide | Pitavastatin | |
|---|---|---|
| Labeled for | HIV | High cholesterol |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $152.87 per tablet 800-150-200-10 mg tablet | $0.954 per tablet 2 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once